Novo Nordisk commits to gender equality
This article was originally published in Scrip
Executive Summary
Novo Nordiskis helping to achieve the United Nations' Millennium Development Goal number 3: to empower women and promote gender equality. The company says that it will help women with diabetes in the developing world through improving the prevention, diagnosis and treatment of the condition. "Women have a higher diabetes-related morbidity and mortality due to biological, cultural and socioeconomic factors … women are often at a disadvantage getting diagnosed and receiving proper treatment," said Lise Kingo, the company's executive vice-president. Novo Nordisk will also co-host a forum on Women, Diabetes and Development in New York alongside the World Diabetes Foundation and the Global Alliance for Women's Health on September 24th.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.